Department of Pediatrics, NewYork-Presbyterian Morgan Stanley Children's Hospital, Columbia University, New York, NY, USA.
Br J Haematol. 2011 Oct;155(2):218-34. doi: 10.1111/j.1365-2141.2011.08822.x. Epub 2011 Aug 16.
Immune reconstitution appears to be delayed following myeloablative conditioning (MAC) and umbilical cord blood transplantation (UCBT) in paediatric recipients. Although reduced toxicity conditioning (RTC) versus MAC prior to allogeneic stem cell transplantation is associated with decreased transplant-related mortality, the effects of RTC versus MAC prior to UCBT on immune reconstitution and risk of graft-versus-host disease (GVHD) are unknown. In 88 consecutive paediatric recipients of UCBT, we assessed immune cell recovery and immunoglobulin reconstitution at days +100, 180 and 365 and analysed risk factors associated with acute and chronic GVHD. Immune cell subset recovery, immunoglobulin reconstitution, and the incidence of opportunistic infections did not differ significantly between MAC versus RTC groups. In a Cox model, MAC versus RTC recipients had significantly higher risk of grade II-IV acute GVHD [Hazard Ratio (HR) 6·1, P = 0·002] as did recipients of 4/6 vs. 5-6/6 HLA-matched UCBT (HR 3·1, P = 0·03), who also had significantly increased risk of chronic GVHD (HR 18·5, P = 0·04). In multivariate analyses, MAC versus RTC was furthermore associated with significantly increased transplant-related (Odds Ratio 26·8, P = 0·008) and overall mortality (HR = 4·1, P = 0·0001). The use of adoptive cellular immunotherapy to accelerate immune reconstitution and prevent and treat opportunistic infections and malignant relapse following UCBT warrants further investigation.
骨髓清除性预处理(MAC)和脐带血移植(UCBT)后,儿科受者的免疫重建似乎延迟。虽然异基因干细胞移植前采用减轻毒性预处理(RTC)而非 MAC 与降低移植相关死亡率相关,但 RTC 与 MAC 在前 UCBT 中对免疫重建和移植物抗宿主病(GVHD)风险的影响尚不清楚。在 88 例连续接受 UCBT 的儿科受者中,我们在第 100、180 和 365 天评估了免疫细胞恢复和免疫球蛋白重建,并分析了与急性和慢性 GVHD 相关的危险因素。MAC 与 RTC 组之间的免疫细胞亚群恢复、免疫球蛋白重建和机会性感染的发生率没有显著差异。在 Cox 模型中,MAC 与 RTC 受者发生 II-IV 级急性 GVHD 的风险显著更高[风险比(HR)6.1,P = 0.002],4/6 与 5-6/6 HLA 匹配的 UCBT 受者也是如此(HR 3.1,P = 0.03),他们发生慢性 GVHD 的风险也显著增加(HR 18.5,P = 0.04)。在多变量分析中,MAC 与 RTC 还与显著增加的移植相关(优势比 26.8,P = 0.008)和总死亡率(HR = 4.1,P = 0.0001)相关。采用过继性细胞免疫疗法加速 UCBT 后的免疫重建,并预防和治疗机会性感染和恶性复发,值得进一步研究。